Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 10/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.37 |
| ▸ | FAP | Q12884 | 4/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.37 |
| ▸ | PREP | P48147 | 2/20 | 0.37 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6944682 | 0.83 | DPP4 (0.33) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL4955995 | 0.83 | DPP4 (0.33) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL5856414 | 0.82 | DPP7 (0.33) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL4951297 | 0.80 | DPP4 (0.33) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL5074820 | 0.79 | ALDH1A1 (0.31) | — | |
| SCHEMBL5874768 | 0.77 | ALDH1A1 (0.32) | — | |
| SCHEMBL11887150 | 0.77 | ALDH1A1 (0.32) | — | |
| SCHEMBL15153153 | 0.77 | ALDH1A1 (0.32) | — | |
| SCHEMBL7718861 | 0.75 | ALDH1A1 (0.36) | — | |
| SCHEMBL12311403 | 0.72 | EPHX2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107474105-B | Preparation method of bulk drug obitasvir | 安徽拜善晟制药有限公司 | 2021-08-31 | — | — | CN | claimed |
| EP-2338490-A2 | Combinations Useful for the Treatment of Neuronal Disorders | Probiodrug AG (DE) | 2011-06-29 | — | — | EP | claimed |
| US-7897633-B2 | Neuronal disorders such as Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function; alcoholism | PROBIODRUG AG (DE) | 2011-03-01 | — | — | US | claimed |
| JP-2007509898-A | — | — | 2007-04-19 | — | — | JP | claimed |
| EP-1680120-A2 | COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS | Probiodrug AG (DE) | 2006-07-19 | — | — | EP | claimed |
| US-20050171112-A1 | Combinations useful for the treatment of neuronal disorders | PROBIODRUG AG | 2005-08-04 | — | — | US | claimed |
| US-20050137142-A1 | Combinations useful for the treatment of neuronal disorders | PROBIODRUG AG | 2005-06-23 | — | — | US | claimed |
| WO-2005049027-A2 | COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS | PROBIODRUG AG (DE) | 2005-06-02 | — | — | WO | claimed |
| CN-116600803-A | Macrocyclic urea orexin receptor agonists | 默沙东有限责任公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-116249697-A | Bicycloheptane pyrrolidine orexin receptor agonists | 默沙东有限责任公司 | 2023-06-09 | — | — | CN | disclosed |
| CN-109642908-B | Compounds useful for treating metabolic disorders | 哈佛学院院长及董事 | 2022-08-16 | — | — | CN | disclosed |
| CN-113388007-A | Ultra-pure agonists of guanylate cyclase C, methods of making and using the same | 博士医疗爱尔兰有限公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-107474105-B | Preparation method of bulk drug obitasvir | 安徽拜善晟制药有限公司 | 2021-08-31 | — | — | CN | disclosed |
| CN-105764916-B | Ultra-pure agonists of guanylate cyclase C, methods of making and using the same | 博士医疗爱尔兰有限公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-1791594-A | 2-aminoquinoline derivatives | BANYU PHARMA CO LTD (JP) | 2006-06-21 | — | — | CN | disclosed |
| CN-1768041-A | Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO INC (US) | 2006-05-03 | — | — | CN | disclosed |
| CN-1700911-A | Combination drug | EISAI CO LTD (JP) | 2005-11-23 | — | — | CN | disclosed |
| US-20050215573-A1 | Novel inhibitors of glutaminyl cyclase | PROBIODRUG AG | 2005-09-29 | — | — | US | disclosed |
| CN-1568190-A | Combination therapy comprising glucose reabsorption inhibitor and PPAR modulator | ORTHO MCNEIL PHARM INC (US) | 2005-01-19 | — | — | CN | disclosed |
| CN-1283108-A | Chlamydia protein, gene sequence and use thereof | ANTEX BIOLOFICS INC (US) | 2001-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171112-A1 | Combinations useful for the treatment of neuronal disorders | MME, DNPEP, DPP4 | SLC7A5 1130/4885DPP4 3/4885DPP7 13/4885 |
| US-20050215573-A1 | Novel inhibitors of glutaminyl cyclase | GLS2, GLS, GLUL | SLC7A5 929/4885DPP4 1062/4885DPP7 1485/4885 |
| US-20050137142-A1 | Combinations useful for the treatment of neuronal disorders | MME, DNPEP, DPP4 | SLC7A5 1239/4885DPP4 3/4885DPP7 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.